Status:
UNKNOWN
Quantitative Prostate Cancer Contrast-enhanced Ultrasound
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Prostate Cancer
Eligibility:
MALE
Phase:
NA
Brief Summary
Background: Bracco has released the VueBoxTM-Prostate software, aimed at distinguishing prostate cancer from prostate benign peripheral zone (PZ) at contrast-enhanced ultrasound (CEUS) using SonoVue® ...
Eligibility Criteria
Inclusion
- Patient referred for prostate biopsy
- Informed consent signed
- Patient affiliated to the French Health Insurance
Exclusion
- History of allergy to SonoVue®
- History of myocardial infarction or angor pectoris
- History of severe pulmonary arterial hypertension (\> 90 mm Hg)
- History of previous treatment for prostate cancer (radiation therapy, brachytherapy, high-intensity focused ultrasound, etc…)
- History of hormone therapy for prostate cancer
Key Trial Info
Start Date :
June 9 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2020
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT02295449
Start Date
June 9 2015
End Date
June 1 2020
Last Update
August 31 2018
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux - Hôpital Pellegrin - Service d'imagerie diagnostique et interventionnelle de l'adulte
Bordeaux, France, 36076 Bordeaux cedex
2
Hospices Civils de Lyon - Hopital Edouard Herriot
Lyon, France, 69003
3
Assistance Publique Hôpitaux de Paris - Hôpital Necker - Service de Radiologie adultes
Paris, France, 75743 Paris cedex 15